Pressure mounts on US FDA to address alleged persistent sexual dysfunction with Merck's hair loss drug
This article was originally published in Scrip
Executive Summary
As physicians call for the US FDA to address reports of persistent sexual dysfunction with Merck & Co's male-pattern hair loss drug Propecia (finasteride), the US Judicial Panel on Multidistrict Litigation in San Diego, California, has scheduled a 29 March hearing session that will determine if a number of individual law suits filed against the company should be "centralised" in one legal action.